Follow us : Twitter LinkedIn
Conseils en Propriété Industrielle / European Patent and Trademark Attorneys
Client Login
Home > Publications > Search for a publication

Search a publication

Title of Intellectual Property
European and Unitary Patent
US Patent
European Union trademark
International Trademark
Domain names
Patentability of Biological Material
Arbitration and Mediation
Regulation, Labelling
Wine and Spirits
Well-known TM, Dilution, Use
Accelerated Examination
European patent
Author name

Search result

5 publications

More revoked patents in the CRISPR/Cas9 saga: The plot thickens

By Lucile VERNOUX and Nicolas BOUQUIN, French & European Patent Attorneys
VERNOUXBOUQUIN.PNG It is getting increasingly difficult to keep track of all the developments of the patent battle around the CRISPR-Cas9 technology. In a new turn of the story, patent EP 3 241 902 owned by University of California has been revoked by an Opposition Division of the European Patent Office.
Published on: 14th Jul 2021

Accelerated examination for anti-COVID patent applications

Par Damien MACE, French & European Patent Attorney
domregimbeau_mace_d_SThumb.jpg With decision n°2021-65, the French Patent Office (INPI), has launched an accelerated examination procedure for patent applications related to an anti-COVID treatment or device, or contributing to the diagnosis or treatment of COVID.
Published on: 10th May 2021

Patentability of Antibodies: The new version of European Guidelines finally contains a dedicated section!

By Cécile PUECH, French and European Patent Attorney
C.PUECH.jpg The new version of the Guidelines for Examination in the EPO, which came into force on March 1st, contains a new section that at last spells out the approach of the EPO concerning the examination of patent applications relating to antibodies.
Published on: 19th March 2021

The NEURIM approach may be restricted or even dismissed. Once again, an advocate general recommends a reversal of jurisprudence. What will the Court's position ultimately be?

By Anne BOUTARIC, Partner.
BOUTARIC_SEARCH.jpg The NEURIM decision opened the possibility to grant SPC for subsequent therapeutic indications of a known active ingredient. This decision, comprising indefinite concepts subject to interpretation, has undermined the objective that Regulation No 469/2009 is uniformly implemented within the European Union. Three requests for a preliminary ruling have since been lodged at the Court of Justice of the European Union leading to the Abraxis judgment delivered on March 21, 2019 and to the Santen case, C-673/18, in progress, in which the Advocate General delivered its opinion on January 23, 2020. The third further pending referral is the Novartis case, C-354/19.
Published on: 28th Jan 2020


CRISPR/CAS9 failed to edit EPO priority entitlement case law

By Nicolas BOUQUIN, French & European Patent Attorney and Lucile VERNOUX French & European Patent Attorney
VERNOUXBOUQUIN.PNG In a new twist in the CRISPR/Cas9 saga, European patent EP 2 771 468 was revoked in appeal on 16 January 2020 (T 0844/18). This patent covers an important aspect of the technology and its use in eukaryotes.
Published on: 28th Jan 2020